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Biology of lymphoma
The pathogenesis of malignant lymphomas remains poorly
understood. Several approaches to detect the genes
involved are available. Bric et al. [1] focus on the detection
of tumor suppressor genes by using RNA interference of
specific gene products in a known mouse model for
lymphoma development. They detected more than 10 new
candidate tumor suppressor genes, showing the validity of
their functional approach. In a similar approach in a
different mouse model, Meacham et al. [2] found many
new gene alterations in a mouse lymphoma, several of
which involved genes associated with cell motility. They
were also able to show that these genes were bona fide drug
targets.
Gloghini et al. [3] studied 14 cell lines and 89 lymphoma
tissues for expression of histone deacetylases (HDAC). In
cell lines, low expression HDAC6 was associated with
growth inhibitory effects of HDAC inhibitors, but it is
rarely expressed in tissue samples of diffuse large B cell
lymphoma (DLBL) and Hodgkin lymphoma (HL).
B cell lymphomas
A crucial element in cancer cells is the unlimited potential
to replicate; thus, cancer cells need telomerase activity for
synthesizing telomeric DNA. Most differentiated cells lack
this activity, but in cancer cells, there is low-level
expression due to altered methylation status of the gene.
In B lymphocytes, the situation is different since they have
telomerase activity and normal methylation status. Bougel
et al. [4] show that by downregulating Pax5, this activity
disappears, indicating the importance of that gene for the
potential of normal B cells to undergo many cell divisions.
The TCL-1 gene is often deregulated in B cell lymphomas
due to hypermethylation of several genes. Balatoni et al. [5]
show that one of these Stk39-encoded proteins (SPAK),
which regulates stress response, is downregulated in B cell
lymphomas resulting in apoptosis resistance.
Chromosomal breaks are dangerous to cells; nevertheless,
they occur often in germinal center B cells. Zhou et al. [6]
found in a mouse model that MDM2, which induces
apoptosis in cells with chromosomal breaks, is downregu-
lated in germinal center B cells due to lack of expression of
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breaks needed for B cell antigen receptor rearrangement.
It is still unclear why the Epstein–Barr virus (EBV) can
resultinsomanydifferentdiseases.Lorenzettietal.[7]l i n k e d
genomic variation of the BZLF1 gene of the virus to 13
cases of lymphoma and 10 of infectious mononucleosis in
children. They were able to find significance but no absolute
difference indicating that other genes or factors are important
too.
Follicular lymphoma (FL) can have various amounts of
diffuse growth areas. Higashi et al. [8] show that the
expression of CD44 and variants is associated with diffuse
areas.
In primary mediastinal large B cell lymphoma and HL,
inactivating mutations in SOCS1, an inhibitor of Janus
kinase/signal transducers and activators of transcription
(JAK/STAT) signaling, contributes to deregulated STAT
activity. Mottok et al. [9] show that these mutations, which
are preferentially targeted to somatic hypermutation hotspot
motifs and frequently inactivating, occur at low level in
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the somatic hypermutation machinery. This was confirmed
by the findingthat a quarter of diffuse large B cell lymphoma
(DLBCL) and FL carried SOCS1 mutations and that only
rare mutations are present in Burkitt lymphoma, plasma-
cytoma, and mantle cell lymphoma (MCL) and none in
tumors of a non-B cell origin.
T cell lymphoma
A specific diet is associated with several forms of cancer,
but there are limited data on the association of food
products and lymphoma development. An interesting study
of Mannini et al. [10] shows that mice fed with maize oil
have a lower lymphoid infiltration of a T cell lymphoma
cell line compared with mice that are fed with fish oil when
an aggressive cell line was used, but there were no
differences in case of a less aggressive cell line. The exact
mechanism remains unclear however.
Anaplastic lymphoma kinase (ALK)-positive anaplastic
large cell lymphoma (ALCL) lacks tumor necrosis factor
(TNF)-alpha expression likely due to promoter methylation.
Demethylation of the promoter in cell lines led to
expression. ALCL cell lines have the TNF-alpha receptor,
and exogenous TNF-alpha induces apoptosis in these cells.
These data combined suggest that treatment of ALCL
patients with a DNA methyltransferase inhibitor might be
an effective approach (Zhang et al. [11]).
Eckerle et al. [12] investigated isolated tumor cells from
ALCL (five ALK-positive, four ALK-negative, and seven
cutaneous) and compared the results with those from HL
and from subsets of T and natural killer (NK) cells. The
results indicate that ALCL derives from activated T cells,
but they had neither a CD8 nor a CD4 gene profile; in fact,
many T cell genes were downregulated. It was remarkable
that there were little differences between all studied
lymphomas even though HL is a B cell neoplasia. It is
therefore questionable whether this approach gives good
insight in the cell of origin of a lymphoma.
Epidemiology of lymphoma
Loberiza et al. [13] investigated whether urban or rural
lymphoma patients have better outcome and whether this
was associated with care given by a university or a
community hospital. In a population-based cohort of
2,330 patients, they found limited differences, indicating
the good organization of care overall. Nevertheless, rural
patients with low and intermediate risk disease treated in a
community hospital had a higher risk of death; in high risk
patients, outcome was better in a university hospital for
urban patients.
Ocular marginal zone lymphomas may be associated
with Chlamydia psittaci. According to Carugi et al. [14],
this the case in an Italian region (17%) but not in a Kenyan
region (0%).
Defining entities
Hodgkin lymphoma and B cell lymphomas
There are clinical, morphological, and phenotypical simi-
larities between HL and primary mediastinal DLBL
(PMLBCL). In the 2008 World Health Organization
(WHO) classification, a separate chapter is dedicated to
cases with features of both, and presently, it remains open
for discussion whether these intermediate cases represent an
entity. Miles et al. [15] investigate the growth factor
receptor-bound protein 2 (Grb2), a molecule that mediates
B cell receptor signaling pathways. In reactive lymphoid
tissues, Grb2 was expressed in the cytoplasm of B cells and
histiocytes but not T cells. Strong cytoplasmic Grb2
expression was seen in FL, chronic lymphocytic leukemia/
small lymphocytic lymphoma (CLL/SLL), splenic marginal
zone lymphoma (SMZL), PMLBCL, DLBL, and nodular
lymphocyte predominant HL. In contrast, only 10% of the
classical HL showed Grb2 expression in the neoplastic
cells. These findings support a role for growth factor
receptor-bound protein 2 in the diagnostically challenging
workup of classical HL versus PMLBCL.
Earlier, Wu et al. [16] had found that JAK2 signaling is
increased in PMLBCL, and thus, they analyzed whether
JAK2 mutations can be found in 31 of these cases, or in
four HL, but found no mutation in JAK2 V617F or exon
12. It remains open to which mechanism upregulates JAK2
in PMLBCL.
Molecular alterations are increasingly important for
treatment choices in CLL/SLL. Garcia et al. [17] tried to
detect morphological features that indicate certain gene
alterations in these cases. Based on the morphological,
phenotypical, fluorescence in situ hybridization (FISH), and
mutational data of 41 cases, they conclude that morpho-
logical features are not reliable in predicting genetic status
even though there is an association between strong ZAP
staining and unmutated immunoglobulin heavy chain.
SMZL is difficult to diagnose, since morphology is
variable; there is no specific immunophenotype, and
involvement of hepatitis C is present in a minority of
cases. The del 7 is common, but not specific. Based on a
comparative genomic hybridization (CGH) array study of
34 patients, 12 of whom were hepatitis C-positive, the most
frequent copy number alterations involved chromosomes 7
and 17 (21% and 24%, respectively). Except for Xp gain,
no differences in common alterations were found between
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cases. Unmutated status of the IgV(H) gene was related to
del(7q) and dup(12q). Poor prognosis was associated with
del(7q) and del(17p).
MCL remains a widely studied lymphoma, and in my
next review, I expect to be able to shed new light on
cyclinD1-negative cases. Mangseth et al. [18] found that
CyclinD3 is lower expressed in MCL than in other small
cell lymphomas, and thus, the ratio cyclinD1/D3 is a better
diagnostic marker. This was needed in their series since
there was considerable overlap between MCL and the other
cases with respect to cyclinD1, a surprising finding.
Increasingly, cyclinD1-negative cases are described,
and Stefancikova [19] describes two such cases that have
the t(11;14). An important new marker for MCL may be
sox11 since it is positive in MCL, regardless of the presence
of t(11;14) and cyclinD1 staining, although it is positive in
multiple myeloma, hairy cell leukemia (HCL), and BL as
well (Chen et al. [20]).Gualco analyzed 127 cases of MCL
for an aberrant phenotype. Since all their cases expressed
cyclinD1, they may have missed negative cases. All their
cases were CD20-positive, 96% had CD5, and 35% were
positive for MUM1, 12% for Bcl6. CD10 was positive in
10% to 20% of the cells in only three cases. Finally, Navarro
et al. [21] confirm that MCL is biologically heterogenous
since they found differences in miRNA expression and
chromosomal alterations between nodal and leukemic cases.
All these data indicate that MCL is on the one hand a prime
example of a well-characterized entity, but on the other hand,
this entity is still heterogenous and contains cases with
aberrant features.
About 5% of myelomas carry the t(14;16) involving the
c-Maf gene, but there is little information on the expression
pattern of this transcription factor. Natkunam et al. [22]
found that it is expressed in about 4% of myelomas, in
HCL (4/4), and in more than half of the T cell and NK/T
cell neoplasias (24/42 and 49/97, respectively).
Plasmablastic lymphoma, extensively discussed at the
recent excellent SH/EAHP workshop in Cleveland, remains
a controversial entity. Bogusz et al. [23] describe three
cases that have a MYC/IgH translocation out of the nine
cases that they have seen in their institute. All three patients
had HIV with a very low number of CD4 cells in their
blood, and all cases had EBV but no HHV8. The prognosis
was very poor. Also in other immunodeficient states, one
sees lymphoproliferations with plasma cell differentiation,
but full plasmacytoma morphology is rare in posttransplant
cases. Richendollar et al. [24], from the Cleveland Clinic,
describe four such cases, all arising extramedullary. These
cases had arisen late after transplantation (mean 7 years);
two of the four had EBV; they were morphologically and
phenotypically very similar to plasmacytoma in immuno-
competent individuals, but bone lesions did not occur.
Three of the patients responded well to reduction of
immune suppression.
Kalungi et al. [25] were able to study 51 cases of BL
from Uganda and found no mutations of the RBL2 gene but
that about 85% of them expressed nuclear pRb2, even
though this is a marker of growth arrest. Apparently, the
myc dysregulation overcomes this growth arrest.
T cell lymphomas
Another well-defined entity is the ALK-negative ALCL. Lu
et al. [26] report four adult cases that present with extensive
peripheral blood and bone marrow involvement, a feature
so far mainly described in children. These cases have a very
poor outcome.
Cutaneous lymphomas
TheCD30-positivecutaneouslymphomasmayariseprimarily
or after transformation from mycosis fungoides (MF). Pham-
Ledard et al. [27] analyzed 54 cases for rearrangement of the
IRF4 gene using FISH. They observed a split FISH signal
pattern indicating a translocation in six out of 23 ALCL
(26%) and two out of 11 transformed MF (18.2%) cases. The
IRF4 expression was not correlated with the presence of
IRF4 alteration in ALCL or T-MF. In contrast to the title of
the study, these data therefore do not indicate that these cases
represent a specific subgroup of cutaneous lymphomas.
New entities/subtypes
Rarely, HL develops after transplantation. Adams et al. [28]
compared eight such cases with classical HL developed in
immune competent individuals. All cases expressed CD15,
CD30, and LMP1. The B cell markers BOB-1, Oct2,
CD79a, and CD20 were more commonly expressed in
posttransplant HL versus cHL (100%, 86%, 50%, and 38%
in ptHL compared to 6%, 14%, 10%, and 33% in cHL,
respectively); all ptHL expressed phosphoinositide 3-kinase
versus 81% of cHL; 2/6 (33%). These limited differences
do not indicate that these cases need a different approach.
Raparia et al. [29] describe the data from 16 patients
with intraocular lymphoma and demonstrate that these can
be adequately classified according to the WHO classifica-
tion. DLBL, CD10-negative and most likely of nongerminal
center B cell-like subgroup, is the most common subtype of
non-Hodgkin lymphoma in this site, in contrast to ocular
adnexal lymphoma for which MALT lymphoma is the most
common subtype.
A multicenter group approached the problem of separating
germinal center from activated B cell lymphomas. Using the
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MTA3, and cyclin D2, they were able to create an algorithm
that predicts the distinction with 93% accuracy, much better
than the 80% of the Hans algorithm (Choi et al. [30]).
By comparing 22 cases of DLBL with a high number of
histiocytes with 96 cases of usual DLBL, Wada et al. [31]
showed that these had a more favorable prognosis and more
often EBV (about 20% versus 5%) but had no other specific
markers.
Bhagavathi et al. [32] did an in depth pathological study
into 21 cases of primary bone DLBL. Since the phenotype,
genetic changes, and subtype (GCB versus activated B)
were highly variable, this is not a separate entity.
Miranda et al. [33] add additional cases to the increasing
number of breast implant associated ALK-negative ALCL.
Out of their six primary breast ALCL, four were ALK-
negative, and three of them associated with a breast implant.
These had a very good outcome, but it was remarkable that
one was a patient with a previous ALCL of the skin.
Kong et al. [34] describe nine cases of cutaneous ALCL
with many neutrophils or eosinophils. These cases can be
difficult to diagnose but are further quite similar to regular
cutaneous ALCL. There were too few cases to give an idea
on prognostic impact of this finding.
Pitfalls in lymphoma diagnosis
Newimmunomodulatingagentsareincreasinglyusedandcan
be associated with lymphoproliferations, often EBV-positive.
Hasserjian etal. [35] collected 18 such cases, including six B
cell lymphomas, two T cell lymphomas, three classical HL,
and seven atypical lymphoproliferations. The results show
that these cases are similar to posttransplant cases and are
often very similar to regular lymphomas, so that knowledge
of the clinical data is crucial.
Kan et al. [36] describe three difficult to diagnose splenic
lymphomas; all three were in patients treated with cortico-
steroids before the splenectomy was performed, indicating
that such treatment affects the morphology of lymphomas.
Prognostic factors in lymphoma
The human germinal center-associated lymphoma gene
(HGAL) has prognostic value in DLBL, and thus, Azambuja
decided to study it in HL as well. In 232 patients with HL,
188 had staining for HGAL in their tumor tissue. The
patients had a more than 82% 5-year survival in contrast to
67% in HDAL-negative cases. In a similar study in 280
cases, Muenst et al. [37] looked for expression of
programmed death-1 (PD-1) and found that the number of
PD-1-positive cells and their location in the tissue were
related to HL subtypes and that patients with a high number
of these cells have a poorer outcome, whereas those with a
high number of FoxP3-positive cells have a better outcome.
Proliferation rate is an important prognostic factor in many
tumors, including MCL. The assessment of the proliferative
index is however rather subjective. In an important paper,
including many experienced European hematopathologists,
Klapper et al. [38] give a precise guideline based on a
detailed interobserver study using different methods, which
is relatively easy to follow, and is based on counting Ki67-
positive cells among 200 tumor cells.
Since vessel targeting has become an important approach
in the management of patients with solid tumors, interest in
the vascularization of lymphomas has increased as well.
Gratzinger et al. [39] studied vascularization parameters in
162 de novo DLBL patients treated with R-CHOP,
including vessel density, vascular endothelial growth factor
(VEGF), and its receptors' expression. There was an
association of VEGFR1 with longer overall survival, and
the authors postulate that VEGFR1 may oppose autocrine
VEGFR2 signaling in DLBCL by competing for VEGF
binding. In contrast to prior results with chemotherapy
alone, microvessel density was not prognostic with R-
CHOP-like therapy.
Gualco et al. [40] studied 16 pediatric and adolescent
nodal DLBL and conclude that they are mainly of the
germinal center type, with a generally good outcome despite
the frequent expression of BCL-2 and the presence of c-MYC
translocation. TCL1 expression seems to be associated with a
good clinical outcome, whereas MUM1 expression predicts a
poor clinical outcome. Obviously, data on such low numbers
need confirmation in larger series.
Obermann et al. [41] looked into the prognostic value of
bcl-2 gene abnormalities and protein expression in DLBL,
using tissue microarrays of 224 cases. They found 40 cases
with a bcl-2 break and 66 with a gain and that they conclude
that cases of the non-GC type with BCL2 gene aberration are
accompanied by a significantly worse prognosis as opposed
to cases without such gene abnormalities. Protein expression
was not indicative for prognosis.
Youssif et al. [42] performed CGH-array in 15 cases of
pediatric ALK-positive ALCL and found that patients with
fewer imbalances had a better outcome but gains in two
regions were associated with a poor survival. Also here, the
low number of cases needs to be taken into account.
Staging
Increasingly FDG-PET is being used in staging and
assessing treatment response in patients with malignant
lymphoma. Imataki compared this method with CT-
scanning in 95 patients and found that the sensitivity and
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shows that there may be differences between lymphoma
types, but the numbers are small.
Ancillary techniques
Since it is easier to obtain cells rather than tissues from
patients, increasingly cytology is being used for diagnosing
or excluding cancer. This approach is becoming more
reliable, thanks to several methods than can be applied to
such specimens. Gupta et al. [43] analyze the morphology
and texture of B cell lymphoma cells in 50 cytological
preparations with morphometry. Using all the morphomet-
ric and textural parameters together, 83.3% of cells could be
correctly classified to a particular NHL subtype. Although
this is not reliable enough for routine practice and the study
is based on a limited number of specimens, the approach
may be refined and can be a promising adjunct. Neverthe-
less, Das et al. [44] show in a study of seven cases of
ALCL that nuclear features can be extremely variable.
A more important role for cytology is the separation of
benignlymphnodesfrommalignantones,andaproteinthatis
differentially expressed between these would be very wel-
come. According to King et al. [45], the insulin-like growth
factor II mRNA binding protein 3 (IMP-3) is such a
molecule. They immunohistochemically evaluated IMP-3
expression in normal lymphoid tissue and 141 lymphomas.
In nonmalignant tissues, IMP-3 expression was restricted to
germinal center B cells. Among lymphoid neoplasms, HL
demonstrated the highest percentage of positive cases (26/26,
100%) often with bright staining. BL was positive in 10
(83%) of 12 cases with moderate to bright staining. Although
FL was also positive in a high percentage of cases (12/15,
80%), the intensity was exclusively weak to moderate.
Although 22 (85%) of 26 of DLBL were positive for IMP-
3, there was wide variability in staining intensity, which did
not correlate with classification into activated B cell versus
germinal center B origin. In contrast, lower proportions (8–
20%) of other nongerminal center B lymphoma subtypes
were IMP-3-positive. In situation where architecture is
lacking, like in cytological preparations, this knowledge
may come in useful, but more studies are needed.
Another technique that is increasingly used, especially
when limited material is available, is flow cytometry. Gujral
et al. [46] were able to compare flow cytometry data from
blood and bone marrow samples with the primary lympho-
ma tissue of 356 B cell lymphoma patients. A limited panel
of nine antibodies, namely CD19, CD5, CD23, CD10,
FMC7, kappa, lambda, CD3, and CD20, could correctly
identify 92% of cases, including CLL, FCL, MCL, and
HCL. This very good result indicated that cytological
specimens can be used, too.
The presence of a chromosomal translocation can facilitate
the correct classification of a lymphoma. Nowadays, this is
mostly done using split signal probes on tissue sections using
immunofluorescence. VanRijketal.[47]d e m o n s t r a t e ,i n5 4 0
lymphoma cases representing 11 lymphoma types, that a
bright field approach is feasible and reliable, which brings
this technique within the reach of each pathology laboratory,
provided that well-trained and dedicated technicians and
pathologists are involved. Although Monaco et al. [48]u s e d
the fluorescent approach, in principle their data indicate that
ISH for chromosomal translocations can be used in cytology
specimens as well. Of their 181 cases, FISH studies were
performed in 106 cases (59%). The indications for FISH
studies were for subclassification (59 cases; 56%) and a
nondiagnostic result (47 cases; 44%). Of the 59 cases
submitted for subclassification, 23 cases (39%) were
successfully subclassified. From the 47 cases which were
nondiagnostic, 26 cases (55%) demonstrated an immuno-
globulin heavy-chain gene rearrangement and/or chromo-
somal translocation, indicating malignant lymphoma.
The diagnosis of angioimmunoblastic T cell lymphoma
(AITL) can be difficult, and the presence of CD3-negative
and CD10-positive cells can be helpful although this
finding is not restricted to this lymphoma entity. Zhang et
al. [49] show that after sorting of these cells and clonality
testing, in early stage of AITL, they were oligoclonal and
became monoclonal as AITL progressed. These findings
illustrate the differences between early and late lymphoma
but also indicate that the diagnosis remains difficult even
after the use of these extensive and expensive techniques.
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